Renovo plc is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research, and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in 2009. The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes.

PropertyValue
dbpedia-owl:Company/industry
dbpedia-owl:Organisation/foundationDate
  • 2000-10-01 00:00:00 (xsd:date)
dbpedia-owl:Organisation/keyPerson
dbpedia-owl:Organisation/keyPersonPosition
  • Mark Ferguson (CEO)
    Sharon O'Kane
dbpedia-owl:Organisation/location
dbpedia-owl:Organisation/type
dbpedia-owl:foundationDate
  • 2000-10-01 00:00:00 (xsd:date)
dbpedia-owl:industry
dbpedia-owl:keyPerson
dbpedia-owl:keyPersonPosition
  • Mark Ferguson (CEO)
    Sharon O'Kane
dbpedia-owl:location
dbpedia-owl:type
dbpprop:abstract
  • Renovo plc is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research, and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in 2009. The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes.
dbpprop:companyName
  • Renovo plc
dbpprop:companyType
dbpprop:foundation
  • October 2000
dbpprop:homepage
dbpprop:industry
dbpprop:keyPeople
dbpprop:location
dbpprop:products
  • 3 in clinical development
dbpprop:reference
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Renovo plc is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research, and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in 2009. The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes.
rdfs:label
  • Renovo plc
skos:subject
foaf:homepage
foaf:name
  • Renovo plc
foaf:page
is dbpprop:redirect of